http://orcid.org/0000-0001-5459-4973
References
- Wasserman M, Palacios MG, Grajales AG, Báez-Revueltas B, Wilson M, McDade C, Farkouh R. Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico. Hum Vaccin Immunother. 2018;1–10. doi: 10.1080/21645515.2018.1516491.
- Wilson M, Wasserman M, Jadavi T, Postma M, Breton MC, Peloquin F, Earnshaw S, McDade C, Sings H, Farkouh R. Clinical and economic impact of a potential switch from 13-Valent to 10-Valent pneumococcal conjugate infant vaccination in Canada. 2018; Infectious Diseases and Therapy, 7(3):353–371.
- Caro JJ, Briggs AH, Siebert U, Kuntz KM, Force I-SMGRPT. Modeling good research practices overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Med Decis Making. 2012;32(5):667–677. doi:10.1177/0272989X12454577.
- de Oliveira LH, Camacho LA, Coutinho ES, Martinez-Silveira MS, Carvalho AF, Ruiz-Matus C, Toscano CM. Impact and effectiveness of 10 and 13-valent pneumococcal conjugate vaccines on hospitalization and mortality in children aged less than 5 years in Latin American Countries: a systematic review. PLoS ONE. 2016 Dec 12;11(12):e0166736. eCollection 2016. Review. doi:10.1371/journal.pone.0166736.
- Cohen O, Knoll M, O’Brien K, Ramakrishnan M, Constenla D, Privor-Dumm L. Pneumococcal conjugate vaccine (PCV) product assessment I.V.A.C. IVAC, Editor. 2017 [Accessed 2018 Oct]. https://www.jhsph.edu/ivac/wpcontent/uploads/2018/05/pcv-product-assessment-april-25-2017.pdf
- WHO Scientific Advisory Group of Experts on Immunization (SAGE). Accessed 2018 Sep 20. http://www.who.int/immunization/sage/regional/en/.
- Deceuninck G, De Serres G, Boulianne N, Lefebvre B, De Wals P. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine. 2015;33(23):2684–2689. doi:10.1016/j.vaccine.2015.04.005.
- Domingues CM, Verani JR, Montenegro Renoiner EI, de Cunto Brandileone MC, Flannery B, de Oliveira LH, Santos JB, de Moraes JC. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med. 2014;2(6):464–471. doi:10.1016/S2213-2600(14)70060-8.
- Jokinen J, Rinta-Kokko H, Siira L, Palmu AA, Virtanen MJ, Nohynek H, Virolainen-Julkunen A, Toropainen M, Nuorti JP, Beall B. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children—a population-based study. PLoS ONE. 2015;10(3):e0120290. doi:10.1371/journal.pone.0120290.
- Organización Panamericana de la Salud (OPS). Informe regional de SIREVA II, 2015. Datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis, en procesos invasores bacterianos. Washington (DC): OPS; 2018. [Accessed 2018 Oct]. https://www.paho.org/hq/index.php?option=com_content&view=article&id=5536:2011-sireva-ii&Itemid=3966&lang=en.
- Instituto Nacional de Salud Pública (INSP). Reporte de serotipos y susceptibilidad antimicrobiana de S. pneumoniae, H. inuenzae y S. aureus. Cuernavaca (México): Instituto Nacional de Salud Pública-Secretaría de Salud; 2016. [Accessed 2018 Oct]. https://www.insp.mx/lineas-de-investigacion/medicamentos-en-salud-publica/sireva.html.